Ronald C. Renaud Jr. - 09 Jun 2026 Form 4 Insider Report for Kailera Therapeutics, Inc. (KLRA)

Reporting relationship: CEO & President, Director
Issuer ticker: KLRA
Reported as of: 09 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Jun 2026, 16:05:10 UTC
Prior SEC filing: 16 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ John Mei, Attorney-in-fact

Key filing fact

Ronald C. Renaud Jr. filed Form 4 for Kailera Therapeutics, Inc. (KLRA) on 11 Jun 2026.

Key facts

This page summarizes Ronald C. Renaud Jr.'s Form 4 filing for Kailera Therapeutics, Inc. (KLRA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 11 Jun 2026, 16:05.

Change

Previous filing in this sequence was filed on 16 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001354434 Primary reporting owner

Renaud Ronald C JR

Relationship: CEO & President, Director
Address: C/O KAILERA THERAPEUTICS, INC., 180 THIRD AVENUE, 4TH FLOOR, WALTHAM
Signature: /s/ John Mei, Attorney-in-fact
Signature date: 11 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KLRA transaction

Common Stock

Options Exercise

Transaction value
Shares: +38,094
Change %
Price: $5.25^*
Shares after: 38,094
Date: 09 Jun 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KLRA transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -38,094
Change %: -4.5%
Price: $0.000000^*
Shares after: 817,826
Date: 09 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 38,094
Exercise price: $5.25
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The options vested and became exercisable as to 33% of the total shares on September 9, 2025 and thereafter in 24 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.